Altre lingue Soligenix, Inc.

Azioni

SNGX

US8342235053

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 26/04/2024			Variaz. 5gg	Var. 1 gen.
0,415 ^USD	-2,81%		-3,71%	-45,19%

25/04	Soligenix estende la protezione del brevetto per la sua piattaforma di vaccini Filovirus al Regno Unito e al Sudafrica	CI
03/04	Soligenix annuncia l'accordo con l'Agenzia Europea dei Medicinali sul disegno del secondo studio confermativo controllato con placebo per Hybryte?	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Soligenix Extends Patent Protection for Its Filovirus Vaccine Platform to the United Kingdom and South Africa	25/04
Soligenix Announces Pricing of $4.75 Million Public Offering	18/04
Sector Update: Health Care Stocks Softer Late Afternoon	15/04
Sector Update: Health Care Stocks Gain Monday Afternoon	15/04
Soligenix Shares Rise After Active Ingredient in MarVax Gets US FDA's Orphan Drug Designation	15/04
Soligenix Shares Rise After SuVax Gets Orphan Drug Designation from US FDA	15/04
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection	15/04
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection	11/04
Soligenix Announces Agreement on the Design of Second Confirmatory Placebo-Controlled Trial for Hybryte? with the European Medicines Agency	03/04
Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency	03/04
Soligenix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15/03
Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results	15/03
Soligenix Announces Formation of Beh et s Disease Medical Advisory Board	09/02
Soligenix, Inc. Announces Formation of Behçet's Disease Medical Advisory Board	08/02
Soligenix to Present at The Microcap Conference	25/01
FDA Grants Soligenix 'Fast Track' Designation for Dusquetide in the Treatment of Oral Lesions of Behcet's Disease	09/01
FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease	08/01
FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease	08/01
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis	04/01
Soligenix Announces Top-Line Results of the Phase 2A Study of Sgx302 (Synthetic Hypericin) in Patients with Mild-To-Moderate Psoriasis	04/01

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Soligenix, Inc.

Azioni

SNGX

US8342235053

Altre lingue

Filtri